Case Reports in Hematology

Case Reports in Hematology / 2014 / Article

Case Report | Open Access

Volume 2014 |Article ID 145129 | 7 pages | https://doi.org/10.1155/2014/145129

A Rare Presentation of In Situ Mantle Cell Lymphoma and Follicular Lymphoma: A Case Report and Review of the Literature

Academic Editor: Sotirios G. Papageorgiou
Received07 Sep 2014
Revised17 Oct 2014
Accepted17 Oct 2014
Published16 Nov 2014

Abstract

A 65-year-old gentleman presented with left groin swelling over the course of two months. Physical exam revealed nontender left inguinal adenopathy, and computed tomography scans detected multiple lymph nodes in the mesenteric, aortocaval, and right common iliac regions. An excisional lymph node biopsy was performed. Pathologic evaluation demonstrated follicular center site which stained positive for PAX5, CD20, CD10, Bcl-2, Bcl-6, and mantle zone cells. These findings demonstrated CCND1 and CD5 positivity, suggesting composite lymphoma comprising follicular lymphoma (FL) with in situ mantle cell lymphoma (MCLIS). FL is known as indolent non-Hodgkin lymphoma; however, the clinical significance of a coexisting MCLIS continues to be elusive, and optimal management of these patients remains largely unknown. This case illustrates the diagnostic and therapeutic challenges of composite lymphomas. This paper also discusses advances in molecular pathogenesis and lymphoma genomics which offer novel insights into these rare diseases.

1. Introduction

Composite lymphoma (CL) is defined by two or more morphologically and immunophenotypically distinct lymphomas observed within the same anatomic site [1]. Only 6 cases of composite FL and MCL lymphoma have been reported to date (Table 1) [27], and FL with coexistent MCLIS cases have only been described in 6 patients (Table 2) [59]. The FL component typically appears to be low grade, harbors the t(14; 18) translocation, and stains positive for Bcl-2 on immunohistochemistry (IHC). The MCL component, however, displays a diffuse or in situ mantle-zone growth pattern, harbors the t(11; 14) translocation, and expresses CCND1 [10, 11]. The incidence of CL ranges from 1–4.7% of total lymphomas and has no gender or ethnic predilection. Here, we add one more case to the rare collection of FL with “in situ” MCL, where such findings are often incidental and associated with indolent clinical course.


Case numberAgeInvolvementImmunohistochemistry staining  TreatmentFollow-upRef
Gender

166 FWaldeyer ring
Tonsil
Pharyngeal wall
Lingual tonsil
Nasal cavity
MCL: CD5+, CD20+, IgD+, cyclinD1+, Bcl-2+, CD3−
FL: CD2+, CD10+, Bcl-2+, Bcl-6+, CD5−
CorticosteroidPET scan every 3–6 months[2]

2MOcular adnexaNANAPoor prognosis mentioned[3]

384 FSpleenFL: CD20+, CD23+, Bcl-6+, CD5−, CD43−, Bcl-2−
MCL: cyclinD1+, CD5−
Splenectomy
Patient refused additional treatment
9 months after splenectomy, CT scan showed intra-abdominal lymphadenopathy and patient died from unknown cause 13 months later[4]

470 FCervical LN
Inguinal LN
CD20+, CD3−, cyclinD1−
50% of B-cell expressed CD5 (MCL)
30% of B-cell expressed CD10 (FL)
No chemotherapyCT of chest and abdomen showed no evidence of lymphadenopathy or hepatosplenomegaly[5]

565 MInguinal LNFL: CD20+, CD79a+, CD10+, Bcl-2+, CD5−, CD230, cyclinD1−, p27+
MCL: CD20+, CD79a+, CD5+, CD10−, CD23−, cyclinD1+, p27−
Interfollicular areas mostly CD5+ showing distinct cylinD1 staining
SplenectomyMCL caused disease progression into spleen. One year after splenectomy, it achieved stable disease[6]

658 FMesenteric LN
Small bowel
MCL: CD5+, CD20+, CD43+
FL: CD10+, CD20+, p27+
22 cycles of chemotherapy over 2 yearsComplete remission[7]


Case numberHistologyImmunohistochemistry
flow cytometry
FISH/southern blot/PCRTissue microdissectionMolecular technique to determine clonal relationshipsResults interpretationRef

1MCL: In situ
FL: LG/G1
In situ MCL: CD5−; cyclin D1+; CD23−
FL: CD10+; BCL2+
NANot doneNot doneNot known[5]

2MCL: In situ
FL: LG/G1
In situ MCL: CD5+; cyclin D1+; CD23−
FL: CD10+; BCL2+
t +
t(14; 18) +
PerformedIgH PCR FR1 FR3 JHClonally related[6]

3MCL: In situ
FL: LG/G1-2, in situ
In situ MCL: CD5−; cyclin D1+; CD23−
FL: CD10+; BCL2−
In situ FL: CD10+; BCL2+
t +
t+
PerformedIgH PCR FR2 D1–6 IgL PCR Vk/KdeClonally related[7]

4MCL: In situ
FL: Stage 4B
In situ MCL: CD5−; cyclin D1+; CD23−
FL: CD10+; BCL2+
NANot doneNot DoneNot known[8]

5MCL: In situ
FL: NA
In situ MCL: CD5+; cyclin D1−; CD23−
FL: CD10+; BCL2+
t +
t +
PerformedPCR for IgHClonally related[9]

6MCL: In situ
FL: NA
In situ MCL: CD5+; cyclin D1+; CD23 NA
FL: CD10+; BCL2+
t +
t +
PerformedPCR for IgHClonally related[9]

2. Case Presentation

A 65-year-old male with a history of gastric bypass surgery and left inguinal hernia repair presented with left groin swelling for two months without any other associated symptoms. He initially presented with an enlarged, palpable, nontender left inguinal lymph node measuring 1 × 1.5 cm. Initial laboratory results, including complete blood count, complete metabolic panel, lactate dehydrogenase, and beta-2-microglobulin, were normal. Computed tomography scan detected multiple lymph nodes in the mesenteric, aortocaval, and right common iliac lymph nodes measuring up to 13 mm in diameter. At the time of surgical evaluation, the inguinal lymph node had regressed and was difficult to pinpoint by physical exam. He, therefore, underwent excisional biopsy of a mesenteric lymph node visible on the CT scan (Figure 1). The follicular center site stained positive for PAX5, CD20, CD10, Bcl-2, and B-cell lymphoma 6 (Bcl-6), indicating follicular lymphoma. However, CCND1 unexpectedly highlighted CD5 positive mantle zone cells in neoplastic follicles, which suggested a MCLIS (Figure 2) component. FISH analysis demonstrated 35% of t(11; 14) and 65% of t(14; 18) in tested nuclei that are mutually exclusive. Further workups including bone marrow biopsy and aspirate were unremarkable. Colonoscopy with random biopsies was negative with no evidence of malignancy although esophagogastroduodenoscopy was not feasible due to his recent gastric bypass surgery. The patient has been followed up for 2 years since initial diagnosis of composite lymphoma and is currently under active clinical surveillance without any signs of disease progression.

3. Discussion

FL is one of the common non-Hodgkin lymphomas with an estimated incidence of 3.18 cases per 100,000 people in the USA [19]. FL can present with asymptomatic lymphadenopathy and bone marrow involvement; however, extranodal involvement is relatively uncommon [20]. FL is the prototype for indolent lymphomas and has a median overall survival of greater than 10 years with current treatment paradigms [20]. FL arises from follicular germinal centers within lymph nodes, when naïve B-cells undergo somatic hypermutation (SHM) in the VH region of the immunoglobulin genes during antigen stimulation. Normally, B-cells with lower affinity to antigen undergo apoptosis (negative selection); however, the FL precursors with t(14; 18) (q32; q21) rearrangement are able to survive through negative selection due to constitutive Bcl-2 overexpression. During SHM, additional point mutations, deletions, and duplications are introduced in the DNA sequence of VH region that can contribute to pathogenesis of FL [21].

MCL is an aggressive and relatively rare lymphoma with an annual incidence of approximately 4–8 cases per million in the USA [22, 23]. 70% of MCL cases present with advanced disease characterized by splenomegaly, nodal, and/or extranodal involvements [24, 25]. A small subset of patients may follow an indolent clinical course, although clinical progression warrants early therapeutic intervention [25, 26]. Morphologically, five cytological variants of MCL have been recognized: classic, small cell, marginal zone-like, pleomorphic, and blastoid. The t(11; 14) (q13; 32) chromosomal rearrangement is the hallmark of MCL, and it results in overexpression of protooncogene, CCND1 [27].

In situ lymphomas are recognized in the WHO classification of both MCL and FL. They are usually incidental findings in reactive-appearing lymph nodes [28]. In situ mantle cell lymphoma (MCLIS) is characterized by CCND1 positive MCL-like cells restricted to the mantle zone of hyperplastic follicles in reactive lymphoid tissues of healthy individuals [12]. MCLIS is extremely rare with only 22 cases reported to date. It has a heterogeneous clinical presentation with 6 cases demonstrating extranodal disease (i.e., lacrimal glands, nasopharynx, oropharynx, and gastrointestinal tract), 1 case with splenic involvement, and bone marrow involvement in 26% of reported cases (Table 3) [8, 1218]. The diagnosis of MCLIS is often made incidentally from biopsies performed during lymphoma workup. Morphologically, the architecture of the lymphoid tissue remains intact and reactive follicles are mainly distributed in the cortical areas. The mantle zones of these follicles are preserved and CCND1 positive cells are often restricted to mantle zones [12].


Case numberAgeSite of biopsyManagementFollow-upStatusCD5Concurrent malignancyRef
Sex

170 MCervical lymph nodeW&W4 yearsOvert MCL[8]
265 FLNChemotherapy0.5 yearsAND[12]
365 MAppendixW&W4 yearsOvert MCL+[12]
466 MPelvic LNW&W4 yearsOvert MCL+Prostate cancer[12]
568 MLN, mediastinalW&W1 yearAWDNot tested[12]
682 MOropharynxW&W3 yearsAWD+CLL/SLL[12]
782 MLymph nodeChemotherapy1.5 yearsAND+CLL/SLL[12]
880 MInguinal LNChemotherapyN/AN/A+CLL/SLL[12]
942 FCervical lymph nodeW&W1 yearAlive with no disease (AND)Breast cancer[12]
1078 FLacrimal glandNot available (NA)NANA+NA[12]
1142 MSupraclavicular LNRadiotherapy1.7 yearsANDCastleman disease[12]
1258 MIntestineChemotherapy1.4 yearsAND+none[12]
1342 FLN, axillary/inguinal, GITChemotherapy6 yearsAND+[13]
1470 FLN, submandibularW&W12 yearsAWD in Peripheral blood (PB)+Nonspecific granulomas[14]
1559 MCervical lymph nodeW&W5 yearsANDPapillary thyroid cancer[15]
1680 MCervical LNChemotherapy1.5 yearsDied+FL[15]
1765 FIntramammary LNChemotherapy5 yearsAND+FL[15]
1865 M AppendixW&W4 yearsMCL +NA[15]
1968 MMediastinal LNW&W1 yearANDNA [15]
2041 FInguinal lymph node (LN)Watch and Wait (W&W)19.5 yearsAlive with disease (AWD)none[16]
2172 FCervical lymph nodeRadiotherapy2 yearsAND+Breast cancer[17]
2234 MLeft supraclavicular LNChemotherapy1 monthDied+FL[18]

W&W: watch and wait.
AND: alive with no disease.
AWD: alive with disease.
NA: nonavailable.
CLL: chronic lymphocytic leukemia.
SLL: small lymphocytic lymphoma.
LN: lymph node.
GIT: gastrointestinal tract.

Most of MCLIS cells can be divided into two groups: CD5-negative and CD5-positive MCLIS. CD5-negative MCLIS can be typically seen in younger patients, where it often presents with nodal involvement and requires no treatment in most cases. On the other hand, CD5-positive MCLIS is associated with older age, extranodal involvement, and other lymphomas. Patients with CD5-positive MCLIS are more likely to require treatment. Interestingly, no difference in survival has been noted between these two groups [15].

The t(11; 14) (q13; q32) rearrangement juxtaposing the protooncogene CCND1 to the immunoglobulin heavy chain (IGH) complex is considered a pivotal event in the development of MCL. This translocation occurs within the bone marrow during pre-B stage differentiation with V (D) J recombination of the IGH variable region (IGHV) [10]. It is hypothesized that the naive B-cell carrying t(11; 14) colonizes the mantle zone of the lymphoid follicle, generating an in situ MCL lesion. Two distinct populations of MCLIS tumors have been recently described. SOX11-positive MCLIS tumors reside in the mantle zone of lymphoid follicles, are genetically unstable, and undergo limited IGHV somatic mutations. Alternatively, SOX11-negative MCLIS tumors are genetically stable and arise from naïve B-cells harboring t(11; 14) which enter the germinal center and undergo IGHV somatic hypermutations. Carvajal-Cuencia et al. found SOX11 expression in 44% of 16 cases with MCLIS and hypothesized that MCLIS may represent an early step in MCL lymphomagenesis [12]. One would presuppose that SOX-positive MCLIS and FL are clonally unrelated and mutually exclusive. However, previous studies show that 15–40% of MCLs carry IGHV hypermutations with a strong bias in the IGHV gene repertoire [29]. Collectively, these results suggest that both lymphomas may originate from the same preneoplastic clone. Unfortunately, depletion of material from confirmatory pathological studies did not permit PCR evaluation for clonality in our patient.

No guidelines have been established for the staging and management of MCLIS. The majority of patients with MCLIS will not develop overt MCL. Therefore, they can be followed up for long periods without treatment [12]. Tumor surveillance with imaging only in the presence of disease-related symptoms or organ involvement appears reasonable. MLCIS must be distinguished from mantle cell lymphoma with a mantle zone pattern and overt mantle cell lymphoma because their treatment approaches vary. Accordingly, staging workup to exclude other sites of involvement or rule out the coexistence of an overt lymphoma is recommended. When FL and MCLIS are reported simultaneously, the dominant lymphoma should be treated when patient requires treatment [30]. Our patient does not meet any indications for treatment, and he has been under active clinical surveillance for 2 years without any signs of disease progression. If there is any evidence of disease progression, we plan to repeat complete staging work-up including a bone marrow and lymph node biopsy with PCR analysis.

4. Conclusion

The significance of MCLIS still remains obscure. At this moment, it is unknown whether MCLIS represents true precursor lesions that will progress to an overt lymphoma or are incidental findings with a low chance of progression. Composite lymphoma with FL and MCLIS can pose diagnostic and therapeutic challenges. However, with new advances in molecular pathology and lymphoma genomics, we have more opportunities to investigate these rare diseases and gain novel insights into their biology in order to benefit the management of affected patients.

Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publishing of this paper.

Authors’ Contribution

Josephine Taverna and Anju Nair contributed equally to this work and share first authorship.

References

  1. H. Kim, “Composite lymphoma and related disorders,” American Journal of Clinical Pathology, vol. 99, no. 4, pp. 445–451, 1993. View at: Google Scholar
  2. R. B. Ilgenfritz, A. le Tourneau, M. Arborio et al., “Composite mantle cell and follicular lymphoma. A case report,” Human Pathology, vol. 40, no. 2, pp. 259–263, 2009. View at: Publisher Site | Google Scholar
  3. A. Looi, R. D. Gascoyne, M. Chhanabhai, J. M. Connors, J. Rootman, and V. A. White, “Mantle cell lymphoma in the ocular adnexal region,” Ophthalmology, vol. 112, no. 1, pp. 114–119, 2005. View at: Publisher Site | Google Scholar
  4. M. R. Roullet, D. Martinez, L. Ma et al., “Coexisting follicular and mantle cell lymphoma with each having an in situ component: a novel, curious, and complex consultation case of coincidental, composite, colonizing lymphoma,” American Journal of Clinical Pathology, vol. 133, no. 4, pp. 584–591, 2010. View at: Publisher Site | Google Scholar
  5. P. Tsang, L. Pan, E. Cesarman, J. Tepler, and D. M. Knowles, “A distinctive composite lymphoma consisting of clonally related mantle cell lymphoma and follicle center cell lymphoma,” Human Pathology, vol. 30, no. 8, pp. 988–992, 1999. View at: Publisher Site | Google Scholar
  6. A. Zamò, R. Zanotti, M. Lestani et al., “Molecular characterization of composite mantle cell and follicular lymphoma,” Virchows Archiv, vol. 448, no. 5, pp. 639–643, 2006. View at: Publisher Site | Google Scholar
  7. F. Fend, L. Quintanilla-Martinez, S. Kumar et al., “Composite low grade B-cell lymphomas with two immunophenotypically distinct cell populations are true biclonal lymphomas: a molecular analysis using laser capture microdissection,” American Journal of Pathology, vol. 154, no. 6, pp. 1857–1866, 1999. View at: Publisher Site | Google Scholar
  8. N. Aqel, F. Barker, K. Patel, and K. N. Naresh, “In-situ mantle cell lymphoma—a report of two cases,” Histopathology, vol. 52, no. 2, pp. 256–260, 2008. View at: Publisher Site | Google Scholar
  9. A. Matsuoka, T. Tsushima, M. Tanibuchi et al., “Composite lymphoma cosisting of mantle cell lymphoma and follicular lymphoma,” Rinshō ketsueki, vol. 54, no. 11, pp. 2056–2061, 2013. View at: Google Scholar
  10. P. Jares, D. Colomer, and E. Campo, “Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics,” Nature Reviews Cancer, vol. 7, no. 10, pp. 750–762, 2007. View at: Publisher Site | Google Scholar
  11. P. Jares, D. Colomer, and E. Campo, “Molecular pathogenesis of mantle cell lymphoma,” The Journal of Clinical Investigation, vol. 122, no. 10, pp. 3416–3423, 2012. View at: Publisher Site | Google Scholar
  12. A. Carvajal-Cuenca, L. F. Sua, N. M. Silva et al., “In situ mantle cell lymphoma: clinical implications of an incidental finding with indolent clinical behavior,” Haematologica, vol. 97, no. 2, pp. 270–278, 2012. View at: Publisher Site | Google Scholar
  13. A. Bassarova, A. Tierens, G. F. Lauritzsen, A. Fosså, and J. Delabie, “Mantle cell lymphoma with partial involvement of the mantle zone: an early infiltration pattern of mantle cell lymphoma?” Virchows Archiv, vol. 453, no. 4, pp. 407–411, 2008. View at: Publisher Site | Google Scholar
  14. B. Espinet, F. Solé, C. Pedro et al., “Clonal proliferation of cyclin D1-positive mantle lymphocytes in an asymptomatic patient: an early-stage event in the development or an indolent form of a mantle cell lymphoma?” Human Pathology, vol. 36, no. 11, pp. 1232–1237, 2005. View at: Publisher Site | Google Scholar
  15. P. Hsu, T. Yang, S. Sheikh-Fayyaz et al., “Mantle cell lymphoma with in situ or mantle zone growth pattern: a study of five cases and review of literature,” International Journal of Clinical and Experimental Pathology, vol. 7, no. 3, pp. 1042–1050, 2014. View at: Google Scholar
  16. L. Nodit, D. W. Bahler, S. A. Jacobs, J. Locker, and S. H. Swerdlow, “Indolent mantle cell lymphoma with nodal involvement and mutated immunoglobulin heavy chain genes,” Human Pathology, vol. 34, no. 10, pp. 1030–1034, 2003. View at: Publisher Site | Google Scholar
  17. S. J. Rodig, B. M. Healey, G. S. Pinkus, F. C. Kuo, P. D. Cin, and J. L. Kutok, “Mantle cell lymphoma arising within primary nodal marginal zone lymphoma: a unique presentation of two uncommon B-cell lymphoproliferative disorders,” Cancer Genetics and Cytogenetics, vol. 171, no. 1, pp. 44–51, 2006. View at: Publisher Site | Google Scholar
  18. Y. Liu, P. Li, Y. Guo, L. Fan, L. Wang, and J. Zhu, “A unique composite follicular lymphoma and mantle cell lymphoma with a mixed cell pattern and aggressive course,” American Journal of Clinical Pathology, vol. 141, pp. 737–741, 2014. View at: Google Scholar
  19. L. M. Morton, S. S. Wang, S. S. Devesa, P. Hartge, D. D. Weisenburger, and M. S. Linet, “Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001,” Blood, vol. 107, no. 1, pp. 265–276, 2006. View at: Publisher Site | Google Scholar
  20. A. Freedman, “Follicular lymphoma: 2011 update on diagnosis and management,” American Journal of Hematology, vol. 86, no. 9, pp. 768–775, 2011. View at: Publisher Site | Google Scholar
  21. R. Kridel, L. H. Sehn, and R. D. Gascoyne, “Pathogenesis of follicular lymphoma,” The Journal of Clinical Investigation, vol. 122, no. 10, pp. 3424–3431, 2012. View at: Publisher Site | Google Scholar
  22. J. O. Armitage, “A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma,” Blood, vol. 89, no. 11, pp. 3909–3918, 1997. View at: Google Scholar
  23. Y. Zhou, H. Wang, W. Fang et al., “Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004,” Cancer, vol. 113, no. 4, pp. 791–798, 2008. View at: Publisher Site | Google Scholar
  24. H. Samaha, C. Dumontet, N. Ketterer et al., “Mantle cell lymphoma: a retrospective study of 121 cases,” Leukemia, vol. 12, no. 8, pp. 1281–1287, 1998. View at: Publisher Site | Google Scholar
  25. J. M. Vose, “Mantle cell lymphoma: 2013 update on diagnosis, risk-stratification, and clinical management,” American Journal of Hematology, vol. 88, no. 12, pp. 1082–1088, 2013. View at: Publisher Site | Google Scholar
  26. P. Martin, A. Chadburn, P. Christos et al., “Outcome of deferred initial therapy in mantle-cell lymphoma,” Journal of Clinical Oncology, vol. 27, no. 8, pp. 1209–1213, 2009. View at: Publisher Site | Google Scholar
  27. F. Bertoni and M. Ponzoni, “The cellular origin of mantle cell lymphoma,” International Journal of Biochemistry and Cell Biology, vol. 39, no. 10, pp. 1747–1753, 2007. View at: Publisher Site | Google Scholar
  28. S. H. Swerdlow, WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues, IARC Press, Lyon, France, 4th edition, 2008.
  29. S. Wang, A. Tzankov, Z. Y. Xu-Monette et al., “Clonally related composite follicular lymphoma and mantle cell lymphoma with clinicopathologic features and biological implications,” Human Pathology, vol. 44, no. 12, pp. 2658–2667, 2013. View at: Publisher Site | Google Scholar
  30. A. Carbone and A. Santoro, “How I treat: diagnosing and managing “in situ” lymphoma,” Blood, vol. 117, no. 15, pp. 3954–3960, 2011. View at: Publisher Site | Google Scholar

Copyright © 2014 Josephine Taverna et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1525 Views | 465 Downloads | 0 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder
 Sign up for content alertsSign up